Muscle Growth & Hormone OptimizationPhase 2 Trials

Ipamorelin

The first selective growth hormone secretagogue -- strong GH release without the cortisol, prolactin, or hunger spikes seen with older peptides.

4 studies referencedClean, selective growth hormone release through the ghrelin receptor pathway

Ipamorelin is a growth hormone releasing peptide that stimulates your pituitary gland to produce more growth hormone. What makes it special is its selectivity. Unlike older peptides in this class, Ipamorelin increases growth hormone without significantly affecting cortisol, prolactin, or other hormones that cause unwanted side effects. Its growth hormone release is comparable to other ghrelin agonists, but it does not spike your stress hormones or cause intense hunger. This clean side effect profile is why it has become the most popular GHRP for stacking with CJC-1295.

The peptide was developed by Novo Nordisk in Denmark and has been called the first selective growth hormone secretagogue. It is a pentapeptide containing just five amino acids, yet despite its small size, it produces significant growth hormone release. Ipamorelin works by mimicking ghrelin, the hunger hormone. It binds to ghrelin receptors in the pituitary gland and triggers growth hormone release, but unlike natural ghrelin, it does not strongly stimulate appetite and does not cause the cortisol and prolactin spikes seen with GHRP-2, GHRP-6, and Hexarelin.

Ipamorelin is not FDA approved. It reached Phase 2 clinical trials for post-operative ileus (gut motility after surgery) but did not meet its primary endpoints and development was discontinued. It remains available through peptide suppliers for research purposes. In studies, even at doses 200 times higher than needed for growth hormone release, Ipamorelin did not increase ACTH (which leads to cortisol) or prolactin. This extraordinary selectivity is what sets it apart from every other injectable growth hormone releasing peptide.

How It Works

Ipamorelin belongs to a class of compounds called growth hormone secretagogues that stimulate growth hormone release through the ghrelin receptor pathway. Your stomach produces a hormone called ghrelin that has several functions: it makes you feel hungry, influences energy balance, and signals the pituitary gland to release growth hormone. The receptor ghrelin binds to is called GHS-R1a. Ipamorelin binds to this same receptor, triggering growth hormone release, but it does so with remarkable selectivity that other GHRPs lack.

After injection, Ipamorelin creates a rapid spike in growth hormone. Levels peak at about 40 minutes and then decline back to baseline. The half-life is approximately 2 hours. This means the effect is quick and temporary, which actually mimics how your body naturally releases growth hormone in pulses. This pulsatile pattern is considered healthier than sustained elevation because it preserves your body's normal feedback systems rather than overriding them.

The growth hormone released by Ipamorelin travels to the liver and stimulates production of IGF-1 (insulin-like growth factor 1). IGF-1 is responsible for many of the anabolic effects: muscle protein synthesis, cellular repair, fat metabolism, and tissue growth. Higher IGF-1 levels over time lead to improvements in body composition, recovery, and overall vitality. When combined with a GHRH peptide like CJC-1295 without DAC, the synergy between the two different receptor pathways produces three to five times more growth hormone than either peptide alone.

Potential Benefits

Growth Hormone Release Without Hormonal Side Effects

Ipamorelin increases growth hormone without raising cortisol, prolactin, or other stress hormones. This is the primary advantage over older peptides like GHRP-6 and GHRP-2. Elevated cortisol interferes with muscle building and promotes fat storage. Elevated prolactin can cause sexual dysfunction and other issues. Ipamorelin avoids both of these problems entirely.

Improved Body Composition

Higher growth hormone and IGF-1 levels support muscle growth and fat loss simultaneously. Users typically report improved ability to build lean mass, reduced body fat especially around the midsection, and better overall body composition. These effects develop gradually over weeks to months of consistent use combined with proper training and nutrition.

Faster Recovery

Growth hormone accelerates tissue repair at the cellular level. This translates to faster recovery between training sessions, reduced muscle soreness, and improved healing from minor injuries. Athletes and fitness enthusiasts often use Ipamorelin specifically for this benefit, as it allows for higher training frequency and intensity.

Better Sleep

Growth hormone release naturally peaks during deep sleep. Ipamorelin, especially when taken before bed, enhances this process. Users commonly report falling asleep faster, sleeping more deeply, and waking up feeling more refreshed. These sleep improvements are often among the first benefits noticed within one to two weeks.

Joint and Connective Tissue Health

IGF-1 stimulates collagen synthesis throughout the body. Over time, this can improve joint comfort, skin quality, and overall connective tissue health. These effects take longer to notice than changes in body composition, typically appearing after two to three months of consistent use.

Bone Health

Ipamorelin has been studied specifically for its effects on bone. Research shows it can counteract bone loss caused by glucocorticoid medications and increase bone formation markers by up to four fold. This makes it particularly relevant for long-term skeletal health, especially in aging populations where bone density naturally declines.

Mild Appetite Effects

Although Ipamorelin activates ghrelin receptors, its effect on hunger is much milder than GHRP-6 or even GHRP-2. Some users notice a slight increase in appetite that can be helpful for eating enough to support muscle gain, while others notice minimal change. This makes it suitable for both bulking and cutting phases.

What the Research Shows

Phase 2 Trials

Raun and colleagues published a landmark study in the European Journal of Endocrinology in 1998 establishing Ipamorelin as the first selective growth hormone secretagogue. The study found that Ipamorelin released growth hormone with potency and efficacy similar to GHRP-6, but unlike GHRP-6 and GHRP-2, it did not increase ACTH or cortisol. This selectivity held even at doses more than 200 times higher than the effective dose for GH release. It had no effect on FSH, LH, prolactin, or TSH.

Gobburu and colleagues published a dose-escalation study in Pharmaceutical Research in 1999 involving 40 healthy male volunteers. The half-life was approximately 2 hours, growth hormone peaked at 40 minutes after injection, there was a dose-dependent response across all tested doses, and the peptide was well tolerated. Andersen and colleagues studied Ipamorelin's effects on bone in 2001 and found it counteracted the glucocorticoid-induced decrease in bone formation, increased bone formation rate by up to four fold, and improved bone mineral content.

Johansen and colleagues published a study in Growth Hormone and IGF Research in 1999 examining longitudinal bone growth in adult female rats. Results showed a dose-dependent increase in bone growth rate from 42 to 52 micrometers per day, pronounced dose-dependent body weight gain, and pituitary growth hormone content remained unchanged, demonstrating no suppression. A 2008 clinical trial by Beck and colleagues studying post-operative ileus in 114 patients found Ipamorelin did not significantly reduce time to first meal compared to placebo, though patients undergoing open surgery showed faster return of GI function.

What to Know

CommonImportantSerious

Injection site redness or irritation, mild flushing, mild water retention, tingling or numbness in the hands that resolves quickly, slight head rush or lightheadedness especially at higher doses, and headache are the most frequently reported side effects. These tend to resolve within the first one to two weeks of use.

Unlike other GHRPs, Ipamorelin does not significantly increase cortisol or prolactin, and it causes minimal appetite stimulation. Fatigue during initial adaptation and vivid dreams may occur but are uncommon. Growth hormone can affect insulin sensitivity, so blood sugar should be monitored if using diabetes medications.

Do not use if you have active cancer or history of cancer, diabetic retinopathy, or are pregnant or breastfeeding. Use caution with diabetes or pre-diabetes, cardiovascular disease, or history of carpal tunnel syndrome. Research on chronic desensitization shows it develops around 16 weeks of continuous use and fully reverses after 4 weeks off.